Effects of ivabradine in patients with coronary artery disease and suffering from a reversible contractility dysfunction of the heart muscle

Effects of oral administration of ivabradine (7.5 mg bid) on post-ischaemic stunning induced by exercise stress in patients with coronary artery disease and exercise inducible ischaemia

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN90566768

Enrollment

Registered

2011-10-18

Start date

2011-09-01

Completion date

Unknown

Last updated

2020-05-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary artery disease Circulatory System Coronary artery disease

Interventions

1. Two film-coated tablets of 7.5 mg or 5 mg of ivabradine 2. Control: placebo bid

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Aged 30 to 75 years 2. Male or female 3. Evidence of coronary artery disease proven by clinical history 4. Sinus rhythm and resting heart rate equal or higher than 70 bpm 5. Exercise-inducible myocardial ischaemia 6. Myocardial stunning, assessed by cardiac echocardiography

Exclusion criteria

Exclusion criteria: 1. Angina at rest or angina class IV 2. Unstable cardiovascular condition 3. Previous treament with anti-anginal medication within 1 week before inclusion 4. Significant abnormalities in the laboratory blood evaluation 5. Contra-indication to the administration of ivabradine

Design outcomes

Primary

Measure	Time frame
1. Myocardial stunning, by evaluating changes in regional wall motion measuring 2D Strain/Strain rate 2. Measured at selection visit, inclusion visit and end of treatment visit	—

Secondary

Measure	Time frame
1. Arterial elastance, measured at selection visit, inclusion visit and end of treatment visit 2. Ventricular arterial coupling, measured at selection visit, inclusion visit and end of treatment visit 3. Safety, measured at each visit	—

Countries

Italy

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026